Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients
Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age 18 or above
• Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min
• Person with Type 2 Diabetes and on insulin
• Access to home wi-fi connection
Locations
United States
California
UC Davis Health
RECRUITING
Sacramento
Contact Information
Primary
Dahlia Zuidema, PharmD
dmzuidema@ucdavis.edu
916-734-4009
Backup
Clinical Research Coordinators
HS-TransplantCenterResearch@ucdavis.edu
916-734-4009
Time Frame
Start Date: 2021-06-29
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 80
Treatments
Active_comparator: Continuous glucose monitoring (CGM)
Those in the intervention arm will wear a continuous glucose monitoring device. They only need to perform blood glucose fingersticks if the CGM transmission is lost for a prolonged period of time or in cases of hypo- or hyperglycemia when symptoms don't align with blood glucose readings.
Placebo_comparator: Self monitoring of blood glucose (fingersticks)
The control arm will remain on standard-of-care SMBG while the intervention arm will use their CGM. The control arm utilizing SMBG will be required to have at minimum 4 glucose checks per day.
Related Therapeutic Areas
Sponsors
Collaborators: DexCom, Inc.
Leads: University of California, Davis